[1]
Barei, F. et al. 2012. From generic to biosimilar drugs: why take an innovative pace?. Farmeconomia. Health economics and therapeutic pathways. 13, 3S (Dec. 2012), 21–27. DOI:https://doi.org/10.7175/fe.v13i3S.328.